PH-L19IL2TNFSCC

What is the Purpose of this Study?

L19IL2/L19TNF

What is the Condition Being Studied?

Advanced Cutaneous Squamous Cell Carcinoma

Who Can Participate in the Study?

People can join this study if they have a confirmed case of locally advanced cutaneous squamous cell carcinoma. They must have at least one tumor on or under the skin that can be measured and injected with the study medicine. They must also have cancer that has gotten worse after taking, or cannot tolerate, a type of treatment called immune checkpoint inhibitors. A team of doctors must agree on this. People can also join if their cancer has spread to nearby areas, such as lymph nodes or skin in between the main tumor area.

Age Group
Adults

What is Involved?

This study wants to find out how well the combination treatment L19IL2/L19TNF works for people with Cutaneous Squamous Cell Carcinoma. Researchers also want to learn how well patients handle the medicine and whether this treatment helps them live longer.

Study Details

Full Title
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment
Principal Investigator
Headshot of Melodi Javid Whitley
Assistant Professor of Dermatology
Protocol Number
IRB: PRO00119223
NCT: NCT07228442
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
INSTITUTIONAL APPROVAL SIGNOFF